- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06125951
Wirkung von 10 mg Xanam auf Demenz aufgrund der Alzheimer-Krankheit (XanaMIA)
Eine doppelblinde, placebokontrollierte, parallele, 36-wöchige, zweiarmige Phase-2b-Studie zur Bewertung der Sicherheit, Verträglichkeit und Wirksamkeit von Xanamem® 10 mg täglich bei Patienten mit leichter oder mittelschwerer Demenz aufgrund der Alzheimer-Krankheit
Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).
This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion. Participants who have completed the main trial will be eligible to participate in an open-label phase, which involves treatment with 10mg Xanamem once daily for a treatment period of up to a maximum of 108 weeks. The OLE is intended to finish when all participants have completed at least 60 weeks of treatment and a follow-up visit 4 weeks later.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
- Phase 3
Kontakte und Standorte
Studienorte
-
-
New South Wales
-
Darlinghurst, New South Wales, Australien
- ACW Investigative Site 106
-
Erina, New South Wales, Australien
- ACW Investigative Site 103
-
Kogarah, New South Wales, Australien
- ACW Investigative Site 102
-
Macquarie Park, New South Wales, Australien
- ACW Investigative Site 107
-
Newcastle, New South Wales, Australien
- ACW Investigative Site 111
-
-
Queensland
-
Birtinya, Queensland, Australien
- ACW Investigative Site 113
-
Chermside, Queensland, Australien
- ACW Investigative Site 105
-
-
South Australia
-
Bedford Park, South Australia, Australien
- ACW Investigative Site 114
-
Woodville South, South Australia, Australien
- ACW Investigative Site 110
-
-
Victoria
-
Carlton, Victoria, Australien
- ACW Investigative Site 115
-
Ivanhoe, Victoria, Australien
- ACW Investigative Site 101
-
Malvern, Victoria, Australien
- ACW Investigative Site 108
-
Parkville, Victoria, Australien
- ACW Investigative Site 112
-
-
Western Australia
-
Nedlands, Western Australia, Australien
- ACW Investigative Site 104
-
West Perth, Western Australia, Australien
- ACW Investigative Site 109
-
-
-
-
California
-
Carlsbad, California, Vereinigte Staaten, 92011
- ACW Investigative Site 218
-
Sherman Oaks, California, Vereinigte Staaten, 91403
- ACW Investigative Site 209
-
-
Colorado
-
Denver, Colorado, Vereinigte Staaten, 80218
- ACW Investigative Site 211
-
Englewood, Colorado, Vereinigte Staaten, 80113
- ACW Investigative Site 208
-
-
Florida
-
Delray Beach, Florida, Vereinigte Staaten, 33445
- ACW Investigative Site 203
-
Miami, Florida, Vereinigte Staaten, 33176
- ACW Investigative site 201
-
New Port Richey, Florida, Vereinigte Staaten, 34652
- ACW Investigative site 202
-
Orlando, Florida, Vereinigte Staaten, 32803
- ACW Investigative site 204
-
The Villages, Florida, Vereinigte Staaten, 32162
- ACW Investigative site 205
-
-
Georgia
-
Decatur, Georgia, Vereinigte Staaten, 30030
- ACW Investigative Site 207
-
-
New Jersey
-
Marlton, New Jersey, Vereinigte Staaten, 08053
- ACW Investigative Site 206
-
-
New York
-
Albany, New York, Vereinigte Staaten, 12208
- ACW Investigative Site 214
-
Staten Island, New York, Vereinigte Staaten, 10314
- ACW Investigative Site 219
-
-
Ohio
-
Dayton, Ohio, Vereinigte Staaten, 45459
- ACW Investigative Site 210
-
Independence, Ohio, Vereinigte Staaten, 44131
- ACW Investigative Site 217
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97225
- ACW Investigative Site 212
-
-
Rhode Island
-
East Providence, Rhode Island, Vereinigte Staaten, 02914
- ACW Investigative Site 216
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78757
- ACW Investigative Site 220
-
-
Washington
-
Bellevue, Washington, Vereinigte Staaten, 98007
- ACW Investigative Site 215
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Male or female aged 50 years or older, inclusive at the time of Screening.
-
Clinical syndrome of mild or moderate dementia, likely to be due to AD in the opinion of the Investigator, at Screening, including meeting the following criteria:
- Clinical Dementia Rating (CDR) global score of 0.5 to 1.0
- Mini-mental state examination (MMSE) score of 18 to 26
- Magnetic resonance imaging (MRI) or computerized tomography (CT) scan within 1 year prior to randomization that excludes alternative diagnoses for dementia such as large stroke, likely vascular dementia, brain tumor, subdural hematoma, or other non-AD dementia type findings
- Positive plasma AD biomarker signature at Pre-screening, comprising fasting levels of a tau species protein.
-
If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to Screening.
-
Has a consenting trial partner who, in the Investigator's judgment, has frequent and sufficient contact with the participant to be able to provide accurate information as to the participant's cognitive and functional abilities. The trial partner must be available to provide information to the Investigator and trial site staff about the participant and agrees to attend all trial site visits in person for scale completion. A trial partner should be available for the duration of the trial. The measure of adequate availability will be at the Investigator's discretion.
-
Participants must be able to comfortably abstain from caffeine intake for 4 hours prior to scheduled cognitive assessments.
-
Smokers are eligible if they are able to comfortably abstain from nicotine / tobacco products for 2 hours prior to scheduled cognitive assessments.
-
Must provide written informed consent to participate in the trial and be willing and able to participate for the maximum of 9 months of treatment and up to 11.5 months of site visits.
Exclusion Criteria:
- Use of anti-amyloid or anti-tau antibody within 6 months.
- Diagnosis of a non-AD dementia including traumatic brain injury.
- Diagnosis of an active major mental illness of concern in the opinion in the Investigator, including major depressive disorder, bipolar illness, or schizophrenia.
- Participation in another clinical trial of a drug or device
- Has a body mass index or body weight that will interfere with participation in the trial, including inadequate venous access to complete the trial assessments, to be determined at the discretion of the Investigator.
- Previous clinically significant systemic illness or infection, including test positive COVID-19, within the past 4 weeks prior to Screening.
- Clinical diagnosis of Type I or Type II diabetes requiring insulin.
- Exhibit physical, cognitive, or language impairments, in the opinion of the Investigator, of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.
- Trial participants with evidence of current infection with HIV, hepatitis B, or hepatitis C.
- Participants with a history of clinically significant drug abuse or addiction in the past 2 years
- Evidence or history of alcohol abuse
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: 10 mg Xanamem
10 mg Xanamem tablet, to be administered orally once every morning with or without food |
Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.
Andere Namen:
|
|
Placebo-Komparator: Placebo
Placebo tablet, to be administered orally once every morning with or without food |
Matching placebo which is identical in appearance to the test product (10 mg Xanamem once daily) except that it contains no active ingredient. |
|
Experimental: Open label phase
Participants enrolled in the open-label phase after the main trial will receive 10 mg Xanamem, to be administered orally once every morning with or without food |
Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Effects of 10 mg Xanamem on integrated cognitive and functional abilities
Zeitfenster: 36 weeks
|
Change from Baseline to end of treatment (EOT) in the Clinical Dementia Ratio - Sum of Boxes (CDR-SB). The CDR-SB is calculated as an average score, with lower scores indicating improvement. |
36 weeks
|
|
Incidence and severity of treatment-emergent adverse events (TEAEs) [safety and tolerability of Xanamem]
Zeitfenster: 36 weeks
|
Incidence and severity of TEAEs |
36 weeks
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Global Program Lead, Actinogen Medical Ltd
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Gehirns
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Psychische Störungen
- Neubildungen
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Neurokognitive Störungen
- Tauopathien
- Neurodegenerative Krankheiten
- Lymphatische Erkrankungen
- Lymphoproliferative Erkrankungen
- Immunproliferative Erkrankungen
- Lymphom, Non-Hodgkin
- Lymphom
- Hämische und lymphatische Krankheiten
- Alzheimer Erkrankung
- Lymphom, follikulär
- Demenz
- UE2343
Andere Studien-ID-Nummern
- ACW0009
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .